Briefing
ZEST stopped early: most ctDNA-positive breast cancers already had radiographic recurrence at staging
In the phase 3 ZEST trial, reported at SABCS 2024, enrollment stopped early after 1,901 patients had a tumor-informed ctDNA result and only 40 were randomized; of 147 patients with ctDNA detected, 72 (49%) already had radiographic recurrence on staging before randomization.